Folate and PSMA Ligand Conjugates for Targeted Radionuclide Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current imaging technologies, such as PET, face challenges in effectively targeting and delivering radionuclides to specific cells like cancer cells overexpressing folate receptors or prostate-specific membrane antigen (PSMA) for accurate diagnosis and monitoring of diseases.
Innovation Solution
Conjugates comprising folate or PSMA ligands complexed with positron-emitting radionuclides, such as 68Ga or 89Zr, are developed to target and deliver radionuclides for PET imaging, allowing for precise delivery into cells overexpressing these receptors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional imaging technologies are used, then general imaging capability is maintained, but targeting precision and delivery efficiency to specific cells are insufficient
Solution Approach 1:
The patent employs ligands as intermediary molecules that specifically bind to overexpressed receptors on target cells (such as folate receptors on cancer cells or PSMA on prostate cancer cells). These ligands act as mediators that guide the radionuclide conjugates to the desired cellular targets, thereby simultaneously improving targeting precision and delivery efficiency without requiring separate targeting and delivery mechanisms
Solution Approach 2:
The invention creates composite conjugates that combine radionuclides with ligands and other functional moieties. These composite structures integrate targeting capabilities (via ligand-receptor binding) with imaging capabilities (via radionuclide emission), enabling both precise targeting and efficient delivery to specific cells in a single unified agent
2Measurement precision
If radionuclides are delivered to specific cells, then imaging accuracy is improved, but specificity and selectivity of cell targeting are challenged
Solution Approach 1:
The patent applies the principle of local quality by designing ligands with specific molecular structures that recognize and bind to particular receptors overexpressed on certain cell types. For example, folate ligands specifically target folate receptors on cancer cells, while PSMA ligands specifically target PSMA on prostate cancer cells. This localized molecular recognition ensures high imaging accuracy while maintaining cell-type specificity
Solution Approach 2:
The invention utilizes parameter changes in the form of selecting different radionuclides with varying half-lives and emission characteristics depending on the specific imaging application and target cell type. This allows optimization of both imaging accuracy and targeting specificity by matching the radionuclide parameters to the biological kinetics of the specific target
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These conjugates enable targeted and effective imaging, diagnosis, and monitoring of various diseases, including cancers, by facilitating the entry of radionuclides into specific cells, thereby enhancing the accuracy of PET imaging.
Implementation Method 1
positron-emitting radionuclides, such as 68Ga or 89Zr
Implementation Method 2
detects pairs of gamma rays emitted indirectly by a positron-producing radionuclide
Implementation Method 3
Because the two emitted gamma rays travel in exactly opposite directions
Implementation Method 4
Following receptor binding of vitamins to vitamin receptors, such as folic acid and analogs and derivatives of folic acid to folate receptors
Implementation Method 5
rapid endocytosis delivers the vitamin into the cell
Implementation Method 6
PSMA is over-expressed in malignant prostate tissues when compared to other organs in the human body
Data Source
AI summary
The invention described herein relates to conjugates and compositions for imaging, diagnosing, and/or monitoring diseases using radionuclide-based imaging. In particular, the invention described herein relates to conjugates and compositions for imaging, diagnosing, and/or monitoring diseases using positron emission tomography.